Tumor Mutational Burden (TMB) is a putative biomarker of response to checkpoint inhibitor therapy. Our TMB assay is a component of our comprehensive immuno-oncology assay portfolio and is available for RUO or GCP applications.
Highlights:
Q2 Solutions TMB levels trend with published TMB levels across different cancer types | |||||||
---|---|---|---|---|---|---|---|
LGG | CHOL | KIRC | COAD | BLCA | LUSC | SKCM | |
Q2 Solutions TMB (WES)1 |
1.5 (N=123) |
2.4 (N=38) |
2.4 (N=100) |
4.6 (N=64) |
8.7 (N=39) |
10.1 (N=258) |
13.2 (N=113) |
Published TMB2 | 1.8 (N=220) |
2.5 (N=1456) |
2.7 (N=543) |
4.5 (N=7758) |
7.2 (N=80) |
9 (N=2102) |
14.4 (N=879) |
1Median TMB scores generated from TCGA whole exome sequencing reads through our pipeline
2 Median TMB scores per Chalmers et al., Genome Medicine 2017
3 https://gdc.cancer.gov/about-data /publications/mc3-2017
LGG=Lower Grade Glioma, CHOL=Cholangiocarcinoma, KIRC=Renal Clear Cell Carcinoma, COAD=Colon Adenocarcinoma, BLCA=Urothelial Carcinoma, LUSC=Lung Squamous Cell Carcinoma,
SKCM=Cutaneous Melanoma, BRCA=Breast Invasive Carcinoma, HNSC=Head-Neck Squamous Cell Carcinoma, LUAD=Lung Adenocarcinoma, SKCM=Cutaneous Melanoma; STAD=Stomach Adenocarcinoma
TMB assay specifications | |
---|---|
Sample Types | Tumor tissue (FFPE, fresh frozen or DNA specimens) Normal tissue, optional (PBMC, whole blood or DNA |
DNA Requirements | 250 ng DNA |
Assay Method | Whole Exome Sequencing |
System Compatibility | NovaSeq 6000, HiSeq 2500 |
Assay Performance | >99.9% accuracy of variant calling for variants above 10% allelic frequency Quantitative precision ≤20% CV% across TMB range of 2-32 |
Deliverables | TMB score, FASTQ, BAM, annotated VCF files |
Our TMB assay is a component of our comprehensive immuno-oncology assay portfolio
Measurement of minimal residual disease (MRD) is one of the best predictors of treatment outcome for leukemia, lymphoma and myeloma.Two approaches of specific interest due to the innovation they...
Author: Victor Weigman, Ph.D., Associate Director, Associate Director, Translational Genomics, Q2 SolutionsThe excitement surrounding immuno-oncology (I-O) is being driven by results seen in the...